Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN

Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase  MSN

Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN

Click here to get full coverage on Just Announced: Akebia Therapeutics Expands Team with 141,800 Share Options at $3.64 Strike Price - Stock Titan

Just Announced: Akebia Therapeutics Expands Team with 141,800 Share Options at $3.64 Strike Price  Stock Titan

Just Announced: Akebia Therapeutics Expands Team with 141,800 Share Options at $3.64 Strike Price - Stock Titan

Click here to get full coverage on Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - Insider Monkey

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees  Insider Monkey

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - Insider Monkey

Click here to get full coverage on Akebia Therapeutics Announces Multiple Positive Business Updates - PR Newswire

Akebia Therapeutics Announces Multiple Positive Business Updates  PR Newswire

Akebia Therapeutics Announces Multiple Positive Business Updates - PR Newswire

Click here to get full coverage on Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 - Seeking Alpha

Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026  Seeking Alpha

Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 - Seeking Alpha

Click here to get full coverage on Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  The Globe and Mail

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail

Click here to get full coverage on Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - PR Newswire

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights  PR Newswire

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - PR Newswire

Click here to get full coverage on Akebia Therapeutics Raises $50M: Major Stock Offering Priced at $2.00 Per Share - Stock Titan

Akebia Therapeutics Raises $50M: Major Stock Offering Priced at $2.00 Per Share  Stock Titan

Akebia Therapeutics Raises $50M: Major Stock Offering Priced at $2.00 Per Share - Stock Titan

Click here to get full coverage on Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock - Yahoo Finance

Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock  Yahoo Finance

Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock - Yahoo Finance

Click here to get full coverage on U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - PR Newswire

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis  PR Newswire

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - PR Newswire

Click here to get full coverage on Akebia Therapeutics Expands Team with Strategic New Hires, Grants $415,000 in Stock Options - Stock Titan

Akebia Therapeutics Expands Team with Strategic New Hires, Grants $415,000 in Stock Options  Stock Titan

Akebia Therapeutics Expands Team with Strategic New Hires, Grants $415,000 in Stock Options - Stock Titan

Click here to get full coverage on H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - Yahoo Finance

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating  Yahoo Finance

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - Yahoo Finance

Click here to get full coverage on Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - PR Newswire

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease  PR Newswire

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - PR Newswire

Click here to get full coverage on Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials - MSN

Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials  MSN

Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials - MSN

Click here to get full coverage on Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?  Yahoo Finance

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Click here to get full coverage on Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  TradingView

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView

Click here to get full coverage on Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates - Yahoo Finance

Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates  Yahoo Finance

Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates - Yahoo Finance

Click here to get full coverage on Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - PR Newswire

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis  PR Newswire

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - PR Newswire

Click here to get full coverage on Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials - Yahoo Finance

Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials  Yahoo Finance

Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials - Yahoo Finance

Click here to get full coverage on There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise - simplywall.st

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise  simplywall.st

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise - simplywall.st

Click here to get full coverage on Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha

Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying  Seeking Alpha

Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha

Click here to get full coverage on Leerink Partners Initiates Coverage of Akebia Therapeutics (AKBA) with Outperform Recommendation - Nasdaq

Leerink Partners Initiates Coverage of Akebia Therapeutics (AKBA) with Outperform Recommendation  Nasdaq

Leerink Partners Initiates Coverage of Akebia Therapeutics (AKBA) with Outperform Recommendation - Nasdaq

Click here to get full coverage on Akebia Therapeutics Expands Team with Strategic Stock Options for 8 Key Hires - Stock Titan

Akebia Therapeutics Expands Team with Strategic Stock Options for 8 Key Hires  Stock Titan

Akebia Therapeutics Expands Team with Strategic Stock Options for 8 Key Hires - Stock Titan

Click here to get full coverage on Akebia Therapeutics Expands Team: Grants $2.41 Stock Options to 8 New Strategic Hires - Stock Titan

Akebia Therapeutics Expands Team: Grants $2.41 Stock Options to 8 New Strategic Hires  Stock Titan

Akebia Therapeutics Expands Team: Grants $2.41 Stock Options to 8 New Strategic Hires - Stock Titan

Click here to get full coverage on Akebia Therapeutics Unveils Major Public Offering: Key Details for Investors - Stock Titan

Akebia Therapeutics Unveils Major Public Offering: Key Details for Investors  Stock Titan

Akebia Therapeutics Unveils Major Public Offering: Key Details for Investors - Stock Titan

Click here to get full coverage on Day 7 of Gains Streak for Akebia Therapeutics Stock with 38% Return (vs. 109% YTD) [6/6/2025] - Trefis

Day 7 of Gains Streak for Akebia Therapeutics Stock with 38% Return (vs. 109% YTD) [6/6/2025]  Trefis

Day 7 of Gains Streak for Akebia Therapeutics Stock with 38% Return (vs. 109% YTD) [6/6/2025] - Trefis

Click here to get full coverage on AKEBIA THERAPEUTICS Earnings Preview: Recent $AKBA Insider Trading, Hedge Fund Activity, and More - Nasdaq

AKEBIA THERAPEUTICS Earnings Preview: Recent $AKBA Insider Trading, Hedge Fund Activity, and More  Nasdaq

AKEBIA THERAPEUTICS Earnings Preview: Recent $AKBA Insider Trading, Hedge Fund Activity, and More - Nasdaq

Click here to get full coverage on AKBA stock touches 52-week high at $2.48 amid robust gains - Investing.com

AKBA stock touches 52-week high at $2.48 amid robust gains  Investing.com

AKBA stock touches 52-week high at $2.48 amid robust gains - Investing.com

Click here to get full coverage on Is Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game? - Yahoo Finance

Is Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game?  Yahoo Finance

Is Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game? - Yahoo Finance

Click here to get full coverage on Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result - Yahoo Finance

Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result  Yahoo Finance

Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result - Yahoo Finance

Click here to get full coverage on Akebia Unveils Critical Cardiovascular Safety Analysis for Vadadustat in Dialysis Patients at ERA Congress - Stock Titan

Akebia Unveils Critical Cardiovascular Safety Analysis for Vadadustat in Dialysis Patients at ERA Congress  Stock Titan

Akebia Unveils Critical Cardiovascular Safety Analysis for Vadadustat in Dialysis Patients at ERA Congress - Stock Titan

Click here to get full coverage on Unphosphorylated STAT1 binds to the BST2 transcription promoter, promoting increased AKBA anchoring on HPMECs to alleviate ARDS - Nature

Unphosphorylated STAT1 binds to the BST2 transcription promoter, promoting increased AKBA anchoring on HPMECs to alleviate ARDS  Nature

Unphosphorylated STAT1 binds to the BST2 transcription promoter, promoting increased AKBA anchoring on HPMECs to alleviate ARDS - Nature

Click here to get full coverage on akba stock - Safe & Smart Way to Grow Money - beatles.ru

akba stock - Safe & Smart Way to Grow Money  beatles.ru

akba stock - Safe & Smart Way to Grow Money - beatles.ru

Click here to get full coverage on Akebia Therapeutics (NASDAQ:AKBA investor five-year losses grow to 80% as the stock sheds US$55m this past week - simplywall.st

Akebia Therapeutics (NASDAQ:AKBA investor five-year losses grow to 80% as the stock sheds US$55m this past week  simplywall.st

Akebia Therapeutics (NASDAQ:AKBA investor five-year losses grow to 80% as the stock sheds US$55m this past week - simplywall.st

Click here to get full coverage on Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - Stock Titan

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights  Stock Titan

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - Stock Titan

Click here to get full coverage on Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates  Yahoo Finance

Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ... - Yahoo Finance

Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ...  Yahoo Finance

Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ... - Yahoo Finance

Click here to get full coverage on Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st

Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next  simplywall.st

Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st

Click here to get full coverage on Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment - Stock Titan

Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment  Stock Titan

Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment - Stock Titan

Click here to get full coverage on Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... - Yahoo Finance

Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ...  Yahoo Finance

Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... - Yahoo Finance

Click here to get full coverage on Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline - Seeking Alpha

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline  Seeking Alpha

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline - Seeking Alpha

Click here to get full coverage on Akebia (AKBA) Publishes Phase 3 Clinical Trial Analysis | AKBA S - GuruFocus

Akebia (AKBA) Publishes Phase 3 Clinical Trial Analysis | AKBA S  GuruFocus

Akebia (AKBA) Publishes Phase 3 Clinical Trial Analysis | AKBA S - GuruFocus

Click here to get full coverage on Akebia's Valuation Looks Stretched Despite Auryxia’s Loss Of Exclusivity (NASDAQ:AKBA) - Seeking Alpha

Akebia's Valuation Looks Stretched Despite Auryxia’s Loss Of Exclusivity (NASDAQ:AKBA)  Seeking Alpha

Akebia's Valuation Looks Stretched Despite Auryxia’s Loss Of Exclusivity (NASDAQ:AKBA) - Seeking Alpha

Click here to get full coverage on Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Stock Titan

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference  Stock Titan

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Stock Titan

Click here to get full coverage on Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwri - GuruFocus

Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwri  GuruFocus

Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwri - GuruFocus

Click here to get full coverage on Kidney Disease Leader Akebia Therapeutics Sets Major Investor Presentation at Jefferies Healthcare Conference - Stock Titan

Kidney Disease Leader Akebia Therapeutics Sets Major Investor Presentation at Jefferies Healthcare Conference  Stock Titan

Kidney Disease Leader Akebia Therapeutics Sets Major Investor Presentation at Jefferies Healthcare Conference - Stock Titan

Click here to get full coverage on Here's Why You Should Consider Buying Akebia (AKBA) Stock - Yahoo Finance

Here's Why You Should Consider Buying Akebia (AKBA) Stock  Yahoo Finance

Here's Why You Should Consider Buying Akebia (AKBA) Stock - Yahoo Finance

Click here to get full coverage on Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript - Insider Monkey

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript  Insider Monkey

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on New Clinical Trial Results Reveal Critical U.S. Patient Data for Akebia's Kidney Disease Treatment - Stock Titan

New Clinical Trial Results Reveal Critical U.S. Patient Data for Akebia's Kidney Disease Treatment  Stock Titan

New Clinical Trial Results Reveal Critical U.S. Patient Data for Akebia's Kidney Disease Treatment - Stock Titan

Click here to get full coverage on Akebia Therapeutics: Q4 Earnings Snapshot - MySA

Akebia Therapeutics: Q4 Earnings Snapshot  MySA

Akebia Therapeutics: Q4 Earnings Snapshot - MySA

Click here to get full coverage on Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines and Strong Vafseo Demand - GuruFocus

Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines and Strong Vafseo Demand  GuruFocus

Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines and Strong Vafseo Demand - GuruFocus

Click here to get full coverage on Akebia Therapeutics' Mysterious 6% Surge: What's Behind the Unexplained Move? - AInvest

Akebia Therapeutics' Mysterious 6% Surge: What's Behind the Unexplained Move?  AInvest

Akebia Therapeutics' Mysterious 6% Surge: What's Behind the Unexplained Move? - AInvest

Click here to get full coverage on Akebia Issues 13,525 Stock Options: What This Means for Shareholder Dilution - Stock Titan

Akebia Issues 13,525 Stock Options: What This Means for Shareholder Dilution  Stock Titan

Akebia Issues 13,525 Stock Options: What This Means for Shareholder Dilution - Stock Titan

Click here to get full coverage on Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering - Yahoo Finance

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering  Yahoo Finance

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering - Yahoo Finance

Click here to get full coverage on AKBA Stock Plummets: Investor Concerns Mount - timothysykes.com

AKBA Stock Plummets: Investor Concerns Mount  timothysykes.com

Akebia Ther (AKBA)

Price Chart

Key Statistics

Technicals

About AKBA

Latest News

Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN

Just Announced: Akebia Therapeutics Expands Team with 141,800 Share Options at $3.64 Strike Price - Stock Titan

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - Insider Monkey

Advanced Charts

Top Gainers

Top Losers